Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0780
0.00 (0.00%)
Sep 11, 2026, 11:11 AM AEST
Neurizon Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | - | - | - | - | 3.38 |
Other Revenue | 17.59 | 1.54 | 0.84 | 0.87 | 1.13 |
| 17.59 | 1.54 | 0.84 | 0.87 | 4.51 | |
Revenue Growth | 1043.54% | 82.70% | -3.66% | -80.63% | 23.33% |
Cost of Revenue | - | - | - | - | 0.31 |
Gross Profit | 17.59 | 1.54 | 0.84 | 0.87 | 4.2 |
Selling, General & Admin | 6.25 | 5.33 | 2.44 | 1.5 | 4.74 |
Research & Development | 21.05 | 12.63 | 3.85 | 1.03 | 0.76 |
Operating Expenses | 27.76 | 18.47 | 6.66 | 2.52 | 5.82 |
Operating Income | -10.17 | -16.94 | -5.82 | -1.65 | -1.62 |
Interest Expense | -0.74 | -0 | - | - | -0.09 |
Interest & Investment Income | 0.18 | 0.34 | 0.02 | 0.08 | 0 |
EBT Excluding Unusual Items | -10.72 | -16.59 | -5.79 | -1.57 | -1.71 |
Asset Writedown | - | - | -3.11 | - | - |
Pretax Income | -10.72 | -16.59 | -8.9 | -1.57 | -1.71 |
Earnings From Continuing Operations | -10.72 | -16.59 | -8.9 | -1.57 | -1.71 |
Earnings From Discontinued Operations | - | - | 1.23 | -4.64 | - |
Net Income | -10.72 | -16.59 | -7.67 | -6.21 | -1.71 |
Net Income to Common | -10.72 | -16.59 | -7.67 | -6.21 | -1.71 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 610 | 487 | 371 | 321 | 317 |
Shares Outstanding (Diluted) | 610 | 487 | 371 | 321 | 317 |
Shares Change | 25.10% | 31.44% | 15.51% | 1.30% | 0.36% |
EPS (Basic) | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 |
EPS (Diluted) | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -15.08 | -14.29 | -5.17 | -1.6 | -1.38 |
Free Cash Flow Per Share | -0.03 | -0.03 | -0.01 | -0.01 | -0.00 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 93.03% |
Operating Margin | -57.83% | -1101.34% | -691.08% | -188.64% | -35.92% |
Profit Margin | -60.98% | -1079.02% | -911.61% | -710.99% | -37.88% |
Free Cash Flow Margin | -85.77% | -929.50% | -614.05% | -183.02% | -30.50% |
EBITDA | -10.17 | -16.94 | -5.82 | -1.32 | -1.45 |
EBITDA Margin | -57.82% | - | - | -151.27% | -32.22% |
D&A For EBITDA | 0 | 0 | 0 | 0.33 | 0.17 |
EBIT | -10.17 | -16.94 | -5.82 | -1.65 | -1.62 |
EBIT Margin | -57.83% | - | - | -188.64% | -35.92% |
Revenue as Reported | - | - | - | - | 4.51 |